A Post-International Gastrointestinal Cancers’ Conference (IGICC) Position Statements

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi:10.1002/ijc.31937
   PubMed Web of Science ®Google Scholar
• Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–2166. doi:10.1111/liv.12818
   PubMed Web of Science ®Google Scholar
• Dogan E, Yalcin S, Koca D, Olmez A. Clinicopathological characteristics of hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev. 2012;13(6):2985–2990. doi:10.7314/APJCP.2012.13.6.2985
   PubMedGoogle Scholar
• Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol. 2021;75(6):1476–1484. doi:10.1016/j.jhep.2021.08.012
   PubMed Web of Science ®Google Scholar
• Barsouk A, Thandra KC, Saginala K, Rawla P, Barsouk A. Chemical Risk Factors of Primary Liver Cancer: an Update. Hepat Med. 2020;12:179–188. doi:10.2147/HMER.S278070
   PubMed Web of Science ®Google Scholar
• McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011;15(2):223–243, vii–x. doi:10.1016/j.cld.2011.03.006
   Web of Science ®Google Scholar
• Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68(3):526–549. doi:10.1016/j.jhep.2017.09.016
   PubMed Web of Science ®Google Scholar
• Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47(4):598–607. doi:10.1016/j.jhep.2007.07.006
   PubMed Web of Science ®Google Scholar
• Yu NC, Chaudhari V, Raman SS, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9(2):161–167. doi:10.1016/j.cgh.2010.09.017
   PubMed Web of Science ®Google Scholar
• Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1(5):431–435. doi:10.1002/hep.1840010511
   PubMed Web of Science ®Google Scholar
• Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696–699. doi:10.1016/0168-8278(95)80226-6
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L: EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB. 2005;7(1):26–34. doi:10.1080/13651820410024049
   PubMedGoogle Scholar
• Chan SL, Mo F, Johnson PJ, et al. Performance of serum alpha-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. HPB. 2014;16(4):366–372. doi:10.1111/hpb.12146
   PubMed Web of Science ®Google Scholar
• Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol. 2006;101(3):524–532. doi:10.1111/j.1572-0241.2006.00443.x
   PubMed Web of Science ®Google Scholar
• Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2010;16(4):418–424. doi:10.3748/wjg.v16.i4.418
   PubMed Web of Science ®Google Scholar
• Park SH, Kim B. Liver Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance. J Liver Cancer. 2020;20(1):25–31. doi:10.17998/jlc.20.1.25
   PubMedGoogle Scholar
• Serste T, Barrau V, Ozenne V, et al. Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology. 2012;55(3):800–806. doi:10.1002/hep.24746
   PubMed Web of Science ®Google Scholar
• Chernyak V, Fowler KJ, Kamaya A, et al. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018;289(3):816–830. doi:10.1148/radiol.2018181494
   PubMed Web of Science ®Google Scholar
• Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922–1965. doi:10.1097/HEP.0000000000000466
   PubMed Web of Science ®Google Scholar
• Cannella R, Dioguardi Burgio M, Sartoris R, Gregory J, Vilgrain V, Ronot M. Adherence to LI-RADS and EASL high-risk population criteria: a systematic review. Hepatology. 2023;77(6):1958–1967. doi:10.1097/HEP.0000000000000321
   PubMed Web of Science ®Google Scholar
• Francica G, Borzio M. Status of, and strategies for improving, adherence to HCC screening and surveillance. J Hepatocell Carcinoma. 2019;6:131–141. doi:10.2147/JHC.S159269
   PubMed Web of Science ®Google Scholar
• Kaur H, Hindman NM, Al-Refaie WB, et al. ACR Appropriateness Criteria((R)) Suspected Liver Metastases. J Am Coll Radiol. 2017;14(5S):S314–S325. doi:10.1016/j.jacr.2017.01.037
   PubMedGoogle Scholar
• MC G, Fowler KJ, Roudenko A, et al. How to Use LI-RADS to Report Liver CT and MRI Observations. Radiographics. 2021;41(5):1352–1367. doi:10.1148/rg.2021200205
   PubMed Web of Science ®Google Scholar
• Veenstra EB, Ruiter SJS, de Haas RJ, et al. A dual-tracer approach using [(11)C]CH and [(18)F]FDG in HCC clinical decision making. EJNMMI Res. 2023;13(1):77. doi:10.1186/s13550-023-01024-y
   PubMed Web of Science ®Google Scholar
• Abouzied MM, Alhinti N, AlMuhaideb A, Al Sugair AS, Al Qahtani M. Extrahepatic metastases from hepatocellular carcinoma: multimodality image evaluation. Nucl Med Commun. 2021;42(6):583–591. doi:10.1097/MNM.0000000000001380
   PubMed Web of Science ®Google Scholar
• Robinson P. Hepatocellular carcinoma: development and early detection. Cancer Imaging. 2008;8:S128–131. doi:10.1102/1470-7330.2008.9019
   PubMedGoogle Scholar
• Gillmore R, Stuart S, Kirkwood A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55(6):1309–1316. doi:10.1016/j.jhep.2011.03.007
   PubMed Web of Science ®Google Scholar
• Becker AK, Tso DK, Harris AC, Malfair D, Chang SD. Extrahepatic metastases of hepatocellular carcinoma: a spectrum of imaging findings. Can Assoc Radiol J. 2014;65(1):60–66. doi:10.1016/j.carj.2013.05.004
   PubMed Web of Science ®Google Scholar
• Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol. 2015;7(12):1632–1651. doi:10.4254/wjh.v7.i12.1632
   PubMed Web of Science ®Google Scholar
• Eschrich J, Kobus Z, Geisel D, et al. The Diagnostic Approach towards Combined Hepatocellular-Cholangiocarcinoma-State of the Art and Future Perspectives. Cancers (Basel). 2023;15(1). doi:10.3390/cancers15010301
   Web of Science ®Google Scholar
• Szpakowski JL, Drasin TE, Lyon LL. Rate of seeding with biopsies and ablations of hepatocellular carcinoma: a retrospective cohort study. Hepatol Commun. 2017;1(9):841–851. doi:10.1002/hep4.1089
   PubMed Web of Science ®Google Scholar
• Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut. 2008;57(11):1592–1596. doi:10.1136/gut.2008.149062
   PubMed Web of Science ®Google Scholar
• Miick R, Minimo C, Bombonati A. Hepatocellular Carcinoma Pathology. In: Hepato-Pancreato-Biliary Malignancies: Diagnosis and Treatment in the 21st Century. edn: Springer; 2022:1–39.
   Google Scholar
• Cutolo C, Dell’Aversana F, Fusco R, et al. Combined Hepatocellular-Cholangiocarcinoma: what the Multidisciplinary Team Should Know. Diagnostics. 2022;12(4).
   Web of Science ®Google Scholar
• Yan BC, Gong C, Song J, et al. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol. 2010;34(8):1147–1154. doi:10.1097/PAS.0b013e3181e5dffa
   PubMed Web of Science ®Google Scholar
• Han X, Huang T, Li Q, Han J, Luo X. Preliminary study on establishing the discriminant equation in pathological grading of hepatocellular carcinoma using immunohistochemical marker parameters. J Cancer Res Ther. 2022;18(5):1320–1327. doi:10.4103/jcrt.jcrt_2021_21
   PubMed Web of Science ®Google Scholar
• Atta IS. Efficacy of expressions of Arg-1, Hep Par-1, and CK19 in the diagnosis of the primary hepatocellular carcinoma subtypes and exclusion of the metastases. Histol Histopathol. 2021;36(9):981–993. doi:10.14670/HH-18-361
   PubMed Web of Science ®Google Scholar
• Huang XY, Zhang JT, Li F, et al. Exosomal proteomics identifies RAB13 as a potential regulator of metastasis for HCC. Hepatol Commun. 2023;7(1):e0006. doi:10.1097/HC9.0000000000000006
   PubMed Web of Science ®Google Scholar
• Kim H, Jang M, Park YN. Histopathological Variants of Hepatocellular Carcinomas: an Update According to the 5th Edition of the WHO Classification of Digestive System Tumors. J Liver Cancer. 2020;20(1):17–24. doi:10.17998/jlc.20.1.17
   PubMedGoogle Scholar
• Zhuo J, Wang Y, Hui H, et al. Enhanced glypican-3-targeted identification of hepatocellular carcinoma with liver fibrosis by pre-degrading excess fibrotic collagen. Acta Biomater. 2023;158:435–448. doi:10.1016/j.actbio.2022.12.062
   PubMed Web of Science ®Google Scholar
• Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–188. doi:10.1111/his.13975
   PubMed Web of Science ®Google Scholar
• Lucatelli P, Guiu B. 2022 Update of BCLC Treatment Algorithm of HCC: what’s New for Interventional Radiologists? Cardiovasc Intervent Radiol. 2022;45(3):275–276. doi:10.1007/s00270-021-03047-1
   PubMed Web of Science ®Google Scholar
• Ho SY, Liu PH, Hsu CY, et al. Comparison of Four Albumin-Based Liver Reserve Models (ALBI/EZ-ALBI/PALBI/PAL) against MELD for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Cancers (Basel). 2023;15(7):1925. doi:10.3390/cancers15071925
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Lacin S, Yalcin S, Karakas Y, et al. Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: a Validation Study. J Hepatocell Carcinoma. 2020;7:143–153. doi:10.2147/JHC.S258930
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab R, Hassan MM, George B, et al. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology. 2020;98(12):836–846. doi:10.1159/000502482
   PubMed Web of Science ®Google Scholar
• Madkhali AA, Fadel ZT, Aljiffry MM, Hassanain MM. Surgical treatment for hepatocellular carcinoma. Saudi J Gastroenterol. 2015;21(1):11–17. doi:10.4103/1319-3767.151216
   PubMed Web of Science ®Google Scholar
• Nault JC, Sutter O, Nahon P, Ganne-Carrie N, Seror O. Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations. J Hepatol. 2018;68(4):783–797. doi:10.1016/j.jhep.2017.10.004
   PubMed Web of Science ®Google Scholar
• Yang B, Zan RY, Wang SY, et al. Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials. World J Surg Oncol. 2015;13:96. doi:10.1186/s12957-015-0516-7
   PubMed Web of Science ®Google Scholar
• Akhan O, Erdemir AG, Karahan S, et al. Long-term results of liver thermal ablation in patients with hepatocellular carcinoma and colorectal cancer liver metastasis regarding spatial features and tumor-specific variables. Diagn Interv Radiol. 2023.
   Google Scholar
• Shin SW, Ahn KS, Kim SW, Kim TS, Kim YH, Kang KJ. Liver Resection Versus Local Ablation Therapies for Hepatocellular Carcinoma Within the Milan Criteria: a Systematic Review and Meta-analysis. Ann Surg. 2021;273(4):656–666. doi:10.1097/SLA.0000000000004350
   PubMed Web of Science ®Google Scholar
• Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012;255(3):405–414. doi:10.1097/SLA.0b013e31824856f5
   PubMed Web of Science ®Google Scholar
• Schwarz C, Plass I, Fitschek F, et al. The value of indocyanine green clearance assessment to predict postoperative liver dysfunction in patients undergoing liver resection. Sci Rep. 2019;9(1):8421. doi:10.1038/s41598-019-44815-x
   PubMed Web of Science ®Google Scholar
• Yao FY, Bass NM, Nikolai B, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl. 2003;9(7):684–692. doi:10.1053/jlts.2003.50147
   PubMed Web of Science ®Google Scholar
• Lingiah VA, Niazi M, Olivo R, Paterno F, Guarrera JV, Pyrsopoulos NT. Liver Transplantation Beyond Milan Criteria. J Clin Transl Hepatol. 2020;8(1):69–75. doi:10.14218/JCTH.2019.00050
   PubMed Web of Science ®Google Scholar
• Abdalla EK, Stuart KE. Overview of Treatment Approaches for Hepatocellular Carcinoma. Waltham, Mass, USA: UpToDate; 2013.
   Google Scholar
• Di Martino M, Ferraro D, Pisaniello D, et al. Bridging therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta‐analysis on intention‐to‐treat outcomes. J Hepato-Biliary-Pancreatic Sci. 2023;30(4):429–438. doi:10.1002/jhbp.1248
   PubMed Web of Science ®Google Scholar
• Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol. 2013;19(43):7515. doi:10.3748/wjg.v19.i43.7515
   PubMed Web of Science ®Google Scholar
• Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl. 2015;21(9):1142–1152. doi:10.1002/lt.24169
   PubMed Web of Science ®Google Scholar
• Galle PR, Tovoli F, Foerster F, Worns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: from surgery to systemic therapy. J Hepatol. 2017;67(1):173–183. doi:10.1016/j.jhep.2017.03.007
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Serviddio G, Muscatiello N. Local ablative treatments for hepatocellular carcinoma: an updated review. World j Gastrointestinal Pharmacol Therapeutics. 2016;7(4):477. doi:10.4292/wjgpt.v7.i4.477
   PubMedGoogle Scholar
• Zavaglia C, Mancuso A, Foschi A, Rampoldi A. High-intensity focused ultrasound (HIFU) for the treatment of hepatocellular carcinoma: is it time to abandon standard ablative percutaneous treatments? Hepatobiliary Surg Nutr. 2013;2(4):184–187. doi:10.3978/j.issn.2304-3881.2013.05.02
   PubMedGoogle Scholar
• Niu LZ, Li JL, Xu KC. Percutaneous Cryoablation for Liver Cancer. J Clin Transl Hepatol. 2014;2(3):182–188. doi:10.14218/JCTH.2014.00017
   PubMedGoogle Scholar
• Herren JL, Disomma N, Ray CE. Interventional Oncology: management of Non-Liver Malignancies: hepatocellular Carcinoma: combined Transarterial Chemoembolization and Ablation. In: Seminars in Interventional Radiology: 2019. Thieme Medical Publishers; 2019:279.
   Google Scholar
• Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16(13):1344–1354. doi:10.1016/S1470-2045(15)00198-9
   PubMed Web of Science ®Google Scholar
• Chen Z, Xie H, Hu M, et al. Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res. 2020;10(9):2993–3036.
   PubMed Web of Science ®Google Scholar
• Salem R, Padia SA, Lam M, et al. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2023;50(2):328–343. doi:10.1007/s00259-022-05956-w
   PubMed Web of Science ®Google Scholar
• Chai NX, Chapiro J. Therapy of Intermediate-Stage Hepatocellular Carcinoma: current Evidence and Clinical Practice. Semin Intervent Radiol. 2020;37(5):456–465. doi:10.1055/s-0040-1719186
   PubMedGoogle Scholar
• Gramenzi A, Golfieri R, Mosconi C, et al. Yttrium‐90 radioembolization vs sorafenib for intermediate‐locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. 2015;35(3):1036–1047. doi:10.1111/liv.12574
   PubMed Web of Science ®Google Scholar
• Arizumi T, Ueshima K, Minami T, et al. Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer. 2015;4(4):253–262. doi:10.1159/000367743
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492–1501. doi:10.1136/gutjnl-2019-318934
   PubMed Web of Science ®Google Scholar
• Lencioni R, Kudo M, Erinjeri J, et al. EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. Am Soc Clin Oncol. 2024;42(3_suppl):LBA432–LBA432. doi:10.1200/JCO.2024.42.3_suppl.LBA432
   Google Scholar
• Idilman I, Peynircioglu B, Cil BE, et al. Transarterial chemoembolization for treatment of hepatocellular carcinoma: a single center experience. Turk J Gastroenterol. 2013;24(2):141–147. doi:10.4318/tjg.2013.0709
   PubMed Web of Science ®Google Scholar
• Lau W-Y, Sangro B, Chen P-J, et al. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology. 2013;84(5):311–318. doi:10.1159/000348325
   PubMed Web of Science ®Google Scholar
• Apisarnthanarax S, Barry A, Cao M, et al. External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline. Practical Radiation Oncol. 2022;12(1):28–51. doi:10.1016/j.prro.2021.09.004
   PubMed Web of Science ®Google Scholar
• Gkika E, Schultheiss M, Bettinger D, et al. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. Radiat Oncol. 2017;12(1):1–11. doi:10.1186/s13014-017-0851-7
   PubMedGoogle Scholar
• Zhang YH, Zhao -Q-Q. Comprehending the therapeutic effects of stereotactic body radiation therapy for small hepatocellular carcinomas based on imagings. Int J Med. 2020.
   Google Scholar
• Kubo K, Kimura T, Aikata H, et al. Long‐term outcome of stereotactic body radiotherapy for patients with small hepatocellular carcinoma. Hepatol Res. 2018;48(9):701–707. doi:10.1111/hepr.13063
   PubMed Web of Science ®Google Scholar
• Katz AW, Chawla S, Qu Z, Kashyap R, Milano MT, Hezel AF. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation. Int J Radiat Oncol. 2012;83(3):895–900. doi:10.1016/j.ijrobp.2011.08.032
   PubMed Web of Science ®Google Scholar
• Liang S-X, Huang X-B, Zhu X-D, et al. Dosimetric predictor identification for radiation-induced liver disease after hypofractionated conformal radiotherapy for primary liver carcinoma patients with Child–Pugh Grade A cirrhosis. Radiother Oncol. 2011;98(2):265–269. doi:10.1016/j.radonc.2010.10.014
   PubMed Web of Science ®Google Scholar
• Benson AB, D’Angelica MI, Abbott DE, et al. NCCN Guidelines Insights: hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15(5):563–573. doi:10.6004/jnccn.2017.0059
   PubMed Web of Science ®Google Scholar
• Dawson LA, Winter KA, Knox JJ, et al. NRG/RTOG 1112: randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC). Am Soc Clin Oncol. 2023;41(4_suppl):489. doi:10.1200/JCO.2023.41.4_suppl.489
   Google Scholar
• Wong TC, Lee VH, Law AL, et al. Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant. Hepatology. 2021;74(5):2580–2594. doi:10.1002/hep.31992
   PubMed Web of Science ®Google Scholar
• Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol. 2017;67(1):92–99. doi:10.1016/j.jhep.2017.02.022
   PubMed Web of Science ®Google Scholar
• Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2(8):565–575. doi:10.1016/S2468-1253(17)30156-5
   PubMed Web of Science ®Google Scholar
• Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47(14):2117–2127. doi:10.1016/j.ejca.2011.05.007
   PubMed Web of Science ®Google Scholar
• Peng Z, Fan W, Zhu B, et al. Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: a Phase III, Randomized Clinical Trial (LAUNCH). J Clin Oncol. 2023;41(1):117–127. doi:10.1200/JCO.22.00392
   PubMed Web of Science ®Google Scholar
• Chiang CL, Chiu KWH, Chan KSK, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):169–178. doi:10.1016/S2468-1253(22)00339-9
   PubMed Web of Science ®Google Scholar
• Kaseb AO, Hasanov E, Cao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):208–218. doi:10.1016/S2468-1253(21)00427-1
   PubMed Web of Science ®Google Scholar
• Lau WY, Ho SK, Yu SC, Lai EC, Liew CT, Leung TW. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg. 2004;240(2):299–305. doi:10.1097/01.sla.0000133123.11932.19
   PubMed Web of Science ®Google Scholar
• Fan J, Tang ZY, Yu YQ, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg. 1998;15(6):674–678. doi:10.1159/000018676
   PubMed Web of Science ®Google Scholar
• Qin S, Chen M, Cheng AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10415):1835–1847. doi:10.1016/S0140-6736(23)01796-8
   PubMed Web of Science ®Google Scholar
• Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75(4):960–974. doi:10.1016/j.jhep.2021.07.004
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. doi:10.1016/S1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Zhu AX, Park JO, Ryoo B-Y, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16(7):859–870. doi:10.1016/S1470-2045(15)00050-9
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296. doi:10.1016/S1470-2045(18)30937-9
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018;379(1):54–63. doi:10.1056/NEJMoa1717002
   PubMed Web of Science ®Google Scholar
• Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873. doi:10.1016/j.jhep.2021.11.030
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Am Soc Clin Oncol. 2022;40(4_suppl). doi:10.1200/JCO.2022.40.4_suppl.379
   Web of Science ®Google Scholar
• Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: a Review in Hepatocellular Carcinoma. Drugs. 2019;79(6):665–674. doi:10.1007/s40265-019-01116-x
   PubMed Web of Science ®Google Scholar
• Yamashita T, Kudo M, Ikeda K, et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020;55(1):113–122. doi:10.1007/s00535-019-01642-1
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995–1008. doi:10.1016/S1470-2045(22)00326-6
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070. doi:10.1056/EVIDoa2100070
   PubMedGoogle Scholar
• Finn R, Kudo M, Merle P, et al. LBA34 Primary results from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2022;33:S1401. doi:10.1016/j.annonc.2022.08.031
   Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90. doi:10.1016/S1470-2045(21)00604-5
   PubMed Web of Science ®Google Scholar
• Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133–1146. doi:10.1016/S0140-6736(23)00961-3
   PubMed Web of Science ®Google Scholar
• Qin S, Chan L, Gu S, et al. LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial. Ann Oncol. 2022;33:S1401–S1402. doi:10.1016/j.annonc.2022.08.032
   Web of Science ®Google Scholar
• Qin S, Finn RS, Kudo M, et al. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncol. 2019;15(16):1811–1822. doi:10.2217/fon-2019-0097
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. doi:10.1016/S0140-6736(16)32453-9
   PubMed Web of Science ®Google Scholar
• Merle P, Blanc JF, Phelip JM, et al. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4(6):454–465. doi:10.1016/S2468-1253(19)30040-8
   PubMed Web of Science ®Google Scholar
• Kelley RK, Ryoo BY, Merle P, et al. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open. 2020;5(4). doi:10.1136/esmoopen-2020-000714
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–952. doi:10.1016/S1470-2045(18)30351-6
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: a Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020;38(3):193–202. doi:10.1200/JCO.19.01307
   PubMed Web of Science ®Google Scholar
• Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J National Compr Cancer Network. 2021;19(5):541–565. doi:10.6004/jnccn.2021.0022
   PubMed Web of Science ®Google Scholar
• Tella SH, Kommalapati A, Mahipal A, Jin Z. First-line targeted therapy for hepatocellular carcinoma: role of atezolizumab/bevacizumab combination. Biomedicines. 2022;10(6):1304. doi:10.3390/biomedicines10061304
   PubMed Web of Science ®Google Scholar
• Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol. 2020;38(36):4317–4345. doi:10.1200/JCO.20.02672
   PubMed Web of Science ®Google Scholar
• Guven DC, Erul E, Sahin TK, Dizdar O, Yalcin S, Sahin IH. The benefit of immunotherapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Future Oncol. 2022;18(37):4119–4136. doi:10.2217/fon-2022-0642
   Web of Science ®Google Scholar
• Llovet J, Ducreux M, Lencioni R, Di Bisceglie A, Galle P, Dufour J. European Association for the Study of the Liver European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943.
   PubMed Web of Science ®Google Scholar